OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Table. 3.

Table. 3.

Performance of UF-5000 parameters, dysmorphic RBC (%), and urinary protein concentration for GH in the derivation and validation cohorts

AUC (95% CI) P Ideal cut-off Derivation cohort Validation cohort*
Sensitivity% (95% CI) Specificity% (95% CI) Sensitivity% (95% CI) Specificity% (95% CI)
URD (%) 0.814 (0.744–0.872) <0.001 >20.1 99.0 (94.6–100) 50.9 (37.1–64.6) 89.4 (76.9–96.5) 63.3 (49.9–75.4)
Small RBC (%) 0.814 (0.744–0.872) <0.001 >30.1 93.1 (86.2–97.2) 60.0 (45.9–73.0) 83.0 (69.2–92.4) 68.3 (55.0–79.7)
Lysed RBC (%) 0.704 (0.626–0.774) <0.001 >1.7 71.3 (61.4–79.9) 61.8 (47.7–74.6) 53.2 (38.1–67.9) 65.0 (51.6–76.9)
RBC-P70FSC (ch) 0.815 (0.745–0.873) <0.001 ≤138 96.0 (90.2–98.9) 56.4 (42.3–69.7) 83.0 (69.2–92.4) 65.0 (51.6–76.9)
RBC-SF-FSC-W (ch) 0.627 (0.546–0.703) 0.017 >30 93.1 (88.2–97.2) 43.6 (30.3–57.7) 87.2 (74.3–95.2) 53.3 (40.0–66.3)
Mean FSC 0.798 (0.725–0.859) <0.001 ≤113 96.9 (91.1–99.4) 52.73 (38.8–66.3) - -
Dysmorphic RBC (%) 0.683 (0.583–0.772) <0.001 >0 61.5 (49.8–72.3) 73.9 (51.6–89.8) 57.7 (36.9–76.7) 37.5 (15.2–64.6)
Urinary protein concentration (mg/L)§ 6.78 (5.83–7.63) 0.021 >190 800 (705–875) 667 (410–867) 702 (551–827) 483 (295–675)

*Sensitivity and specificity in the validation cohort were calculated by applying the cut-off obtained from the derivation cohort; Mean FSC and SSC values were not obtained in validation cohort; 101 and 42 of samples had accompanying dysmorphic RBC(%) results in the derivation and validation cohorts, respectively; §113 and 76 of samples had accompanying urinary protein concentration results in the derivation and validation cohorts, respectively.

Abbreviations: GH, glomerular hematuria; AUC, area under the curve; CI, confidence interval; URD, urinary RBC distribution; RBC, red blood cell; SF, surface channel; FSC, forward-scattered light; ch, channel; W, width.

Ann Lab Med 2022;42:160~168 https://doi.org/10.3343/alm.2022.42.2.160

© Ann Lab Med